Vanda Pharmaceuticals (VNDA) Retained Earnings: 2010-2025
Historic Retained Earnings for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Sep 2025 value amounting to -$253.6 million.
- Vanda Pharmaceuticals' Retained Earnings fell 49.71% to -$253.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$253.6 million, marking a year-over-year decrease of 49.71%. This contributed to the annual value of -$174.3 million for FY2024, which is 12.16% down from last year.
- Per Vanda Pharmaceuticals' latest filing, its Retained Earnings stood at -$253.6 million for Q3 2025, which was down 9.78% from -$231.0 million recorded in Q2 2025.
- In the past 5 years, Vanda Pharmaceuticals' Retained Earnings registered a high of -$153.0 million during Q3 2023, and its lowest value of -$253.6 million during Q3 2025.
- In the last 3 years, Vanda Pharmaceuticals' Retained Earnings had a median value of -$164.1 million in 2024 and averaged -$179.3 million.
- Per our database at Business Quant, Vanda Pharmaceuticals' Retained Earnings increased by 16.80% in 2021 and then plummeted by 49.71% in 2025.
- Quarterly analysis of 5 years shows Vanda Pharmaceuticals' Retained Earnings stood at -$164.2 million in 2021, then increased by 3.82% to -$157.9 million in 2022, then climbed by 1.59% to -$155.4 million in 2023, then fell by 12.16% to -$174.3 million in 2024, then slumped by 49.71% to -$253.6 million in 2025.
- Its Retained Earnings stands at -$253.6 million for Q3 2025, versus -$231.0 million for Q2 2025 and -$203.8 million for Q1 2025.